Kymab is a biopharmecutical company founded in 2010. The company was started in parntership by Professor Allan Bradley and Dr Glenn A Friedrich. Kymab is developing human antibody based therapies using embryonic stem cell technology.
Kymab raises a $40,000,000 series B round from Bill & Melinda Gates Foundation and Wellcome Trust.
Kymab raises a $30,400,000 series A round from Wellcome Trust.
Dr Glenn A Friedrich
Professor Allan Bradley
Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery
E Lee, Qi Liang, Hanif Ali, Luke Bayliss, Alastair Beasley, Tara Bloomfield-Gerdes, Laura Bonoli, Richard Brown, Jamie Campbell, Adam Carpenter, Sara Chalk, Alison Davis, Nick England, Alla Fane-Dremucheva, Bettina Franz, Volker Germaschewski, Helen Holmes, Steve Holmes, Ian Kirby, Miha Kosmac, Anais Legent, Hui Lui, Anais Manin, Siobhan O'leary, Jemima Paterson, Rocco Sciarrillo, Anneliese Speak, Dominik Spensberger, Laura Tuffery, Nikole Waddell, Wei Wang, Sophie Wells, Vivian Wong, Andrew Wood, Michael J Owen, Glenn A Friedrich, Allan Bradley
April 4, 2014
Documentaries, videos and podcasts